» Articles » PMID: 24671712

Engineering Pre-SUMO4 As Efficient Substrate of SENP2

Overview
Date 2014 Mar 28
PMID 24671712
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

SUMOylation, one of the most important protein post-translational modifications, plays critical roles in a variety of physiological and pathological processes. SENP (Sentrin/SUMO-specific protease), a family of SUMO-specific proteases, is responsible for the processing of pre-SUMO and removal of SUMO from conjugated substrates. SUMO4, the latest discovered member in the SUMO family, has been found as a type 1 diabetes susceptibility gene and its maturation is not understood so far. Despite the 14 amino acid differences between pre-SUMO4 and SUMO2, pre-SUMO4 is not processed by SENP2 but pre-SUMO2 does. A novel interdisciplinary approach involving computational modeling and a FRET-based protease assay was taken to engineer pre-SUMO4 as a substrate of SENP2. Given the difference in net charge between pre-SUMO4 and pre-SUMO2, the computational framework analysis of electrostatic similarities of proteins was applied to determine the contribution of each ionizable amino acid in a model of SENP2-(pre-SUMO4) binding, and to propose pre-SUMO4 mutations. The specificities of the SENP2 toward different pre-SUMO4 mutants were determined using a quantitative FRET assay by characterizing the catalytic efficiencies (kcat/KM). A single amino acid mutation made pre-SUMO4 amenable to SENP2 processing and a combination of two amino acid mutations made it highly accessible as SENP2 substrate. The combination of the two approaches provides a powerful protein engineering tool for future SUMOylation studies.

Citing Articles

An ISG15-Based High-Throughput Screening Assay for Identification and Characterization of SARS-CoV-2 Inhibitors Targeting Papain-like Protease.

Samrat S, Kumar P, Liu Y, Chen K, Lee H, Li Z Viruses. 2024; 16(8).

PMID: 39205213 PMC: 11359932. DOI: 10.3390/v16081239.


Mutational signatures in GATA3 transcription factor and its DNA binding domain that stimulate breast cancer and HDR syndrome.

El-Assaad A, Dawy Z, Khalil A, Nemer G Sci Rep. 2021; 11(1):22762.

PMID: 34815386 PMC: 8611019. DOI: 10.1038/s41598-021-01832-z.


Recent advances in user-friendly computational tools to engineer protein function.

Sequeiros-Borja C, Surpeta B, Brezovsky J Brief Bioinform. 2020; 22(3).

PMID: 32743637 PMC: 8138880. DOI: 10.1093/bib/bbaa150.


Gender-specific association of functional 68 bp repeats with cannabis exposure in an African American cohort.

Yuferov V, Butelman E, Kreek M Neuropsychiatr Dis Treat. 2018; 14:1025-1034.

PMID: 29713172 PMC: 5909790. DOI: 10.2147/NDT.S159954.


SUMO, a small, but powerful, regulator of double-strand break repair.

Garvin A, Morris J Philos Trans R Soc Lond B Biol Sci. 2017; 372(1731).

PMID: 28847818 PMC: 5577459. DOI: 10.1098/rstb.2016.0281.


References
1.
Bacher S, Schmitz M . The NF-kappaB pathway as a potential target for autoimmune disease therapy. Curr Pharm Des. 2004; 10(23):2827-37. DOI: 10.2174/1381612043383584. View

2.
Ashida R, Tominaga K, Sasaki E, Watanabe T, Fujiwara Y, Oshitani N . AP-1 and colorectal cancer. Inflammopharmacology. 2005; 13(1-3):113-25. DOI: 10.1163/156856005774423935. View

3.
Guo D, Han J, Adam B, Colburn N, Wang M, Dong Z . Proteomic analysis of SUMO4 substrates in HEK293 cells under serum starvation-induced stress. Biochem Biophys Res Commun. 2005; 337(4):1308-18. DOI: 10.1016/j.bbrc.2005.09.191. View

4.
Dolinsky T, Nielsen J, McCammon J, Baker N . PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 2004; 32(Web Server issue):W665-7. PMC: 441519. DOI: 10.1093/nar/gkh381. View

5.
Wang C, She J . SUMO4 and its role in type 1 diabetes pathogenesis. Diabetes Metab Res Rev. 2007; 24(2):93-102. DOI: 10.1002/dmrr.797. View